6 research outputs found
Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
Membrane lipid switches: How membrane lipid structure influences protein-lipid interactions.
[eng] Peripheral membrane proteins are required for signal propagation upon ligand-induced receptor activation at the plasma membrane. The translocation of this amphitropic peripheral proteins from or to the plasma membrane enables signal cascade propagation into the cells. This translocation greatly depends on the membrane's lipid composition and, consequently, regulation of the lipid bilayer emerges as a novel therapeutic strategy. Indeed, relevant changes in membrane lipids can induce massive translocation of peripheral signaling proteins from or to the plasma membrane, which controls how cells behave. We called these changes 'lipid switches', as they alter the cell's status (e.g., proliferation, differentiation, death, etc.) in response to the modulation of membrane lipids. This discovery enables therapeutic interventions focused on modifying the bilayer's lipids, an approach known as membrane-lipid therapy (MLT) or melitherapy
The implications for cells of the lipid switches driven by protein-membrane interactions and the development of membrane lipid therapy
[eng] The cell membrane contains a variety of receptors that interact with signaling molecules. However, agonist-receptor interactions not always activate a signaling cascade. Amphitropic membrane proteins are required for signal propagation upon ligand-induced receptor activation. These proteins localize to the plasma membrane or internal compartments; however, they are only activated by ligand-receptor complexes when both come into physical contact in membranes. These interactions enable signal propagation. Thus, signals may not propagate into the cell if peripheral proteins do not co-localize with receptors even in the presence of messengers. As the translocation of an amphitropic protein greatly depends on the membrane's lipid composition, regulation of the lipid bilayer emerges as a novel therapeutic strategy. Some of the signals controlled by proteins non-permanently bound to membranes produce dramatic changes in the cell's physiology. Indeed, changes in membrane lipids induce translocation of dozens of peripheral signaling proteins from or to the plasma membrane, which controls how cells behave. We called these changes "lipid switches", as they alter the cell's status (e.g., proliferation, differentiation, death, etc.) in response to the modulation of membrane lipids. Indeed, this discovery enables therapeutic interventions that modify the bilayer's lipids, an approach known as membrane-lipid therapy (MLT) or melitherapy
2-Hydroxy-Docosahexaenoic Acid Is Converted Into Heneicosapentaenoic Acid via α-oxidation: Implications for Alzheimer's Disease Therapy
[eng] Alzheimer's disease (AD) is a neurodegenerative disease with as yet no efficient therapies, the pathophysiology of which is still largely unclear. Many drugs and therapies have been designed and developed in the past decade to stop or slow down this neurodegenerative process, although none has successfully terminated a phase-III clinical trial in humans. Most therapies have been inspired by the amyloid cascade hypothesis, which has more recently come under question due to the almost complete failure of clinical trials of anti-amyloid/tau therapies to date. To shift the perspective for the design of new AD therapies, membrane lipid therapy has been tested, which assumes that brain lipid alterations lie upstream in the pathophysiology of AD. A hydroxylated derivative of docosahexaenoic acid was used, 2-hydroxydocosahexaenoic acid (DHA-H), which has been tested in a number of animal models and has shown efficacy against hallmarks of AD pathology. Here, for the first time, DHA-H is shown to undergo α-oxidation to generate the heneicosapentaenoic acid (HPA, C21:5, n-3) metabolite, an odd-chain omega-3 polyunsaturated fatty acid that accumulates in cell cultures, mouse blood plasma and brain tissue upon DHA-H treatment, reaching higher concentrations than those of DHA-H itself. Interestingly, DHA-H does not share metabolic routes with its natural analog DHA (C22:6, n-3) but rather, DHA-H and DHA accumulate distinctly, both having different effects on cell fatty acid composition. This is partly explained because DHA-H α-hydroxyl group provokes steric hindrance on fatty acid carbon 1, which in turn leads to diminished incorporation into cell lipids and accumulation as free fatty acid in cell membranes. Finally, DHA-H administration to mice elevated the brain HPA levels, which was directly and positively correlated with cognitive spatial scores in AD mice, apparently in the absence of DHA-H and without any significant change in brain DHA levels. Thus, the evidence presented in this work suggest that the metabolic conversion of DHA-H into HPA could represent a key event in the therapeutic effects of DHA-H against AD
2-Hydroxy-Docosahexaenoic Acid Is Converted Into Heneicosapentaenoic Acid via α-Oxidation: Implications for Alzheimer’s Disease Therapy
Alzheimer’s disease (AD) is a neurodegenerative disease with as yet no efficient
therapies, the pathophysiology of which is still largely unclear. Many drugs and
therapies have been designed and developed in the past decade to stop or slow
down this neurodegenerative process, although none has successfully terminated a
phase-III clinical trial in humans. Most therapies have been inspired by the amyloid
cascade hypothesis, which has more recently come under question due to the almost
complete failure of clinical trials of anti-amyloid/tau therapies to date. To shift the
perspective for the design of new AD therapies, membrane lipid therapy has been
tested, which assumes that brain lipid alterations lie upstream in the pathophysiology
of AD. A hydroxylated derivative of docosahexaenoic acid was used, 2-hydroxydocosahexaenoic acid (DHA-H), which has been tested in a number of animal models and has shown efficacy against hallmarks of AD pathology. Here, for the first time,
DHA-H is shown to undergo α-oxidation to generate the heneicosapentaenoic acid
(HPA, C21:5, n-3) metabolite, an odd-chain omega-3 polyunsaturated fatty acid that
accumulates in cell cultures, mouse blood plasma and brain tissue upon DHA-H
treatment, reaching higher concentrations than those of DHA-H itself. Interestingly,
DHA-H does not share metabolic routes with its natural analog DHA (C22:6, n-3) but
rather, DHA-H and DHA accumulate distinctly, both having different effects on cell fatty
acid composition. This is partly explained because DHA-H α-hydroxyl group provokes
steric hindrance on fatty acid carbon 1, which in turn leads to diminished incorporation
into cell lipids and accumulation as free fatty acid in cell membranes. Finally, DHA-H
administration to mice elevated the brain HPA levels, which was directly and positively
correlated with cognitive spatial scores in AD mice, apparently in the absence of DHA-H
and without any significant change in brain DHA levels. Thus, the evidence presented in
this work suggest that the metabolic conversion of DHA-H into HPA could represent a
key event in the therapeutic effects of DHA-H against AD
2-Hydroxy-Docosahexaenoic Acid Is Converted Into Heneicosapentaenoic Acid via α-Oxidation: Implications for Alzheimer’s Disease Therapy
Alzheimer’s disease (AD) is a neurodegenerative disease with as yet no efficient
therapies, the pathophysiology of which is still largely unclear. Many drugs and
therapies have been designed and developed in the past decade to stop or slow
down this neurodegenerative process, although none has successfully terminated a
phase-III clinical trial in humans. Most therapies have been inspired by the amyloid
cascade hypothesis, which has more recently come under question due to the almost
complete failure of clinical trials of anti-amyloid/tau therapies to date. To shift the
perspective for the design of new AD therapies, membrane lipid therapy has been
tested, which assumes that brain lipid alterations lie upstream in the pathophysiology
of AD. A hydroxylated derivative of docosahexaenoic acid was used, 2-hydroxydocosahexaenoic acid (DHA-H), which has been tested in a number of animal models and has shown efficacy against hallmarks of AD pathology. Here, for the first time,
DHA-H is shown to undergo α-oxidation to generate the heneicosapentaenoic acid
(HPA, C21:5, n-3) metabolite, an odd-chain omega-3 polyunsaturated fatty acid that
accumulates in cell cultures, mouse blood plasma and brain tissue upon DHA-H
treatment, reaching higher concentrations than those of DHA-H itself. Interestingly,
DHA-H does not share metabolic routes with its natural analog DHA (C22:6, n-3) but
rather, DHA-H and DHA accumulate distinctly, both having different effects on cell fatty
acid composition. This is partly explained because DHA-H α-hydroxyl group provokes
steric hindrance on fatty acid carbon 1, which in turn leads to diminished incorporation
into cell lipids and accumulation as free fatty acid in cell membranes. Finally, DHA-H
administration to mice elevated the brain HPA levels, which was directly and positively
correlated with cognitive spatial scores in AD mice, apparently in the absence of DHA-H
and without any significant change in brain DHA levels. Thus, the evidence presented in
this work suggest that the metabolic conversion of DHA-H into HPA could represent a
key event in the therapeutic effects of DHA-H against AD